K
Koichiro Ohmura
Researcher at Kyoto University
Publications - 184
Citations - 7612
Koichiro Ohmura is an academic researcher from Kyoto University. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 37, co-authored 157 publications receiving 6004 citations.
Papers
More filters
Journal ArticleDOI
A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects
Chikashi Terao,Koichiro Ohmura,Yuta Kochi,Katsunori Ikari,Etsuko Maruya,Masaki Katayama,Kota Shimada,Akira Murasawa,Shigeru Honjo,Kiyoshi Takasugi,Keitaro Matsuo,Kazuo Tajima,Akari Suzuki,Kazuhiko Yamamoto,Shigeki Momohara,Hisashi Yamanaka,Ryo Yamada,Hiroo Saji,Fumihiko Matsuda,Tsuneyo Mimori +19 more
TL;DR: In this large-scale association study multiple alleles and diplotypes were found to be associated with susceptibility to, or protection against, ACPA-negative RA.
Journal Article
Hemopoietic progenitors in the murine fetal liver capable of rapidly generating T cells.
TL;DR: In this article, the hemopoietic progenitors in fetal liver (FL) compared with those in adult bone marrow (BM) for their ability to differentiate into T, B, and myeloid cells.
Journal ArticleDOI
Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis.
Motomu Hashimoto,Takao Fujii,Masahide Hamaguchi,Moritoshi Furu,Hiromu Ito,Chikashi Terao,Keiichi Yamamoto,Wataru Yamamoto,Takashi Matsuo,Masato Mori,Koichiro Ohmura,Hiroshi Kawabata,Tsuneyo Mimori +12 more
TL;DR: TCZ therapy is an independent factor associated with the increase of Hb level after biologic therapies in RA patients, which will help in selecting appropriate biologics for RA patients with anemia.
Journal ArticleDOI
A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept
Yuki Ishikawa,Naoichiro Yukawa,Daisuke Kawabata,Koichiro Ohmura,Takao Fujii,Takashi Usui,Tsuneyo Mimori +6 more
TL;DR: The patients and the abovementioned reports strongly suggest that onset of overt PM/DM or antisynthetase syndrome in RA patients with anti-aminoacyl tRNA synthetase antibodies is associated withAnti-TNF therapy.
Journal ArticleDOI
Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.
M. Nakano,Takao Fujii,Motomu Hashimoto,Naoichiro Yukawa,Hajime Yoshifuji,Koichiro Ohmura,A. Nakaizumi,Tsuneyo Mimori +7 more
TL;DR: Type I IFN‐induced chemokines may be involved in the pathophysiology of pulmonary vascular diseases, and the JAK inhibitor may serve as a therapeutic option for these diseases.